|
Seminar luncheon
[Webcast]Development of Multivalent Protein Conjugates as a Strategy to Engineer Drug Pharmacology
Speakers:
Wesley Jackson, PhD (CEO, Valitor Bio) & Jesse McFarland, PhD (Director Process Development, Valitor)
Organizers:
Date:
2020-04-10
Time:
12:00-13:30 Pacific Time
Registration fee:
Free
Location:
Webcast
Major Sponsor:
Vendor show vendors registered to date:
(1)Alturas Analytics
Registration: http://www.PBSS.org
Registration deadline:2020-04-09
(it will close sooner if the seating cap is reached)
About the Topic
Valitor is a biotechnology company that has pioneered a unique and robust biophysics-based approach for engineering therapeutic proteins into next-generation drug products. Our multivalent protein (MVP) conjugation technology enables the production of soluble, nanoscale clusters of proteins conjugated to single-chain biopolymers. The pharmacology of MVP conjugates is influenced by both the bioactivity of the therapeutic proteins and the biophysics of the biopolymer. Unlike monovalent protein-polymer conjugation (e.g., Pegylation, which extends serum half-life), our technology enhances a wide range of pharmacological properties, including enhanced in vivo stability, longer target-tissue residence time, and longer durations of therapeutic bioactivity. In this seminar, we will describe the development of our platform technology and the process of advancing it as a pipeline of drug products. About the SpeakersWesley M. Jackson, Ph.D., Chief Executive Officer, Valitor, Inc.
Dr. Jackson began working in biotechnology product development over 10 years ago as a part of a research partnership between the NIH and the Department of Defense. In 2010, he co-founded Valitor as biotechnology company that has pioneered a unique and robust biophysics-based approach for engineering therapeutic proteins into next-generation drug products. Valitor’s core technology was originally invented at UC Berkeley in the laboratories of his co-founders: Profs. Kevin Healy and David Schaffer. Dr. Jackson is now directing the R&D to commercialize this technology by developing drugs that will improve the treatment of diseases in many medical fields, including ophthalmology, orthopedics, and immuno-oncology. Dr. Jackson received a B.S. from the Department of Bioengineering at UC Berkeley, and he received a Ph.D. from the Joint Graduate Program in Bioengineering at UCSF and UC Berkeley.
Jesse M. McFarland, Ph.D., Director of Process Development, Valitor, Inc.
Dr. Jesse M. McFarland obtained his BA in Chemistry from Cornell University and his PhD in Chemistry from UC Berkeley in the lab of Matthew B. Francis. His graduate research focused on the development of novel bioconjugation reactions and the analysis of the complex products formed by those reactions. Dr. McFarland performed his post-doctoral studies with Jack Taunton at UC San Francisco. There, he worked towards the identification of covalent, yet reversible inhibitors of the kinase BTK. Since then, Dr. McFarland has worked at several companies developing therapeutics ranging from antibody drug conjugates to small molecules. Dr. McFarland is a co-author of 12 peer-reviewed publications and a co-inventor of 6 patents. His work has lead to two therapeutics currently undergoing clinical testing.
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Online Workshop] Career Transition for Research Scientists
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|